• Other
  • Exited

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Its lead peptide product candidate, setmelanotide, is a potent, first-in-class melanocortin-4 (MC4) receptor agonist for the treatment of rare genetic disorders of obesity. Rhythm believes that setmelanotide, for which it has exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of MC4 pathway deficiencies.  Its development efforts are initially focused on two of these deficiencies— Prader-Willi syndrome and pro-opiomelanocortion deficiency —for which there are currently no effective or approved treatments. Rhythm believes that the MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight, and that peptide therapeutics are uniquely suited to activating this target.